MINIREVIEWS

170 COVID-19 vaccination and myocarditis: A review of current literature

176 Air leaks in COVID-19
Juneja D, Kataria S, Singh O

SYSTEMATIC REVIEWS

186 COVID-19 pandemic effects on the distribution of healthcare services in India: A systematic review

CASE REPORT

198 COVID-19 presenting with persistent hiccup and myocardial infarction in a peritoneal dialysis patient: A case report

LETTER TO THE EDITOR

204 Management of SARS-CoV-2 infection is a major challenge in patients with lymphoid malignancies: Warrants a clear therapeutic strategy
Sahu T, Verma HK, Lvks B

208 Chemsex and its risk factors associated with human immunodeficiency virus among men who have sex with men in Hong Kong
Chan ASW, Tang PMK, Yan E

212 Cautious optimism in anticipation of hepatitis B curative therapies
Turshudzhan A, Tadros M

216 “Heart failure in COVID-19 patients: Critical care experience”: A letter to the editor
Tsikgou V, Siasos G, Oikonomou E, Bletsas E, Vavuranakis M, Tousoulis D
ABOUT COVER
Editorial Board Member of World Journal of Virology, Shahid Akhtar Siddiqui, MBBS, MD, Assistant Professor, Doctor, Department of Pediatrics, MLN Medical College, King George Medical University, Lucknow, Allahabad 211002, Uttar Pradesh, India. sha.akht@yahoo.com

AIMS AND SCOPE
The primary aim of World Journal of Virology (WJV, World J Virol) is to provide scholars and readers from various fields of virology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJV mainly publishes articles reporting research results obtained in the field of virology and covering a wide range of topics including arbovirus infections, viral bronchiolitis, central nervous system viral diseases, coinfection, DNA virus infections, viral encephalitis, viral eye infections, chronic fatigue syndrome, animal viral hepatitis, human viral hepatitis, viral meningitis, opportunistic infections, viral pneumonia, RNA virus infections, sexually transmitted diseases, viral skin diseases, slow virus diseases, tumor virus infections, viremia, and zoonoses.

INDEXING/ABSTRACTING
The WJV is now abstracted and indexed in PubMed, PubMed Central, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Yu-Xi Chen; Production Department Director: Xiang Li; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL
World Journal of Virology

ISSN
ISSN 2220-3249 (online)

LAUNCH DATE
February 12, 2012

FREQUENCY
Bimonthly

EDITORS-IN-CHIEF
Mahmoud El-Bendary, En-Qiang Chen

EDITORIAL BOARD MEMBERS
https://www.wjgnet.com/2220-3249/editorialboard.htm

PUBLICATION DATE
July 25, 2022

COPYRIGHT
© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/GerInfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/GerInfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/GerInfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/GerInfo/239

ONLINE SUBMISSION
https://www.f6publishing.com

© 2022 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com
Management of SARS-CoV-2 infection is a major challenge in patients with lymphoid malignancies: Warrants a clear therapeutic strategy

Tarun Sahu, Henu Kumar Verma, Bhaskar Lvks

Tarun Sahu, Physiology, All India Institute of Medical Science, Raipur 492001, Chhattisgarh, India

Henu Kumar Verma, Department of Immunopathology, Institute of Lung Health and Immunity, Comprehensive Pneumology Center, Helmholtz Zentrum, Munich 80331, Bayren, Germany

Bhaskar Lvks, Zoology, Guru Ghasidas Vishwavidyalaya, Bilaspur 495001, Chhattisgarh, India

Corresponding author: Henu Kumar Verma, PhD, Research Scientist, Department of Immunopathology, Institute of Lung Health and Immunity, Comprehensive Pneumology Center, Helmholtz Zentrum, Ingolstädter Landstrasse 1, Munich 80331, Bayren, Germany, henu.verma@yahoo.com

Abstract

Patients with lymphoma malignancies are at a higher risk of coronavirus disease 2019 (COVID-19) infection due to their immunocompromised state and results in higher mortality rates in these patients. Anti-CD 20 therapy is one of the leading causes of immunosuppression that worsens in COVID-19 cases. COVID-19 vaccines, on the other hand, appear to be less beneficial to these patients. Appropriate treatment and recommendations are required for these COVID-19 patients with lymphoid malignancies.

Key Words: COVID-19; Lymphoid malignancy; Lymphoma; Vaccination; Immunosuppression

Core Tip: Patients with hematologic conditions are two times more likely than others to be admitted to the hospital. They are being treated with anti-cancer drugs, which weakens their immune system. As a result, these patients are always at risk of coronavirus disease 2019 (COVID-19). As we know, the COVID-19 is very lethal, and hematological malignancies are likely to increase the risk of negative outcomes from this viral infection. Currently, there are no guidelines for treating COVID-19 infected patients with hematological malignancies.
TO THE EDITOR

In March 2019, the World Health Organization declared the novel coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2, as a pandemic. Nearly one-third of patients with lymphoid malignancies experienced severe complications of COVID-19 and required hospitalization[1,2]. According to the 2017 World Health Organization classification, there are more than 80 different types of mature lymphoma, which are divided into three major categories: B-cell neoplasms, T-cell and natural killer cell neoplasms, and Hodgkin lymphomas[3]. We recently read the paper from Riches[4] entitled “Impact of COVID-19 in patients with lymphoid malignancies” in your prestigious journal “World Journal of Virology”. I sincerely thank the author for providing vital information about the effect of COVID-19 in patients with lymphoid malignancies.

Patients with lymphoid malignancies are highly susceptible to COVID-19 infection because they are already immunocompromised due to active cancer treatments. In this review article, the author mainly focused on the impact of COVID-19 on chronic lymphocytic leukemia, which is the most common form of leukemia in western countries[5]. In the present article the author included case studies, cohort studies, systematic reviews, and meta-analyses. Several lines of evidence suggested that the type of hematological malignancy and target antineoplastic therapy, older age, and various preexisting conditions such as hypertension and diabetes are all linked to mortality in lymphoma patients[6-8]. A retrospective study of 343 patients with hematologic malignancies and hematopoietic stem cell transplantation found that severe acute respiratory syndrome coronavirus 2 infection progressed to pneumonia in 119 patients (35%), including those with leukemia, those over the age of 65 years, and those with severe neutropenia or lymphopenia. It also found that more than 85% of patients with lymphoid malignancies required hospital admission, with 9% admitted to the intensive care unit and an overall mortality rate of 34.5%[9].

The information available on the effects of COVID-19 in patients with various hematologic diseases is limited. A series of case reports of COVID-19 patients with various hematological malignancies increases the risk of adverse complications due to immunosuppression caused by the underlying cancer and treatment effects[10-13].

The author does not have much data to show the impact of lymphoma on COVID-19 vaccination at the time of writing his paper. In this context, we would like to mention two recent studies that analyzed the efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia and multiple myeloma. According to these studies, BNT162b2 mRNA COVID-19 vaccine negatively affects the production of neutralizing antibodies in patients treated with anti-chronic lymphocytic leukemia and anti-myeloma therapies[14-16]. As hematologic malignancies are life-threatening conditions and the majority of the medications are immunosuppressive agents that progress to the severe/critical stage and collapse of patients, data for medications in these conditions with COVID-19 are limited[17,18]. To avoid severe conditions and death, researchers/clinicians must develop an appropriate medication guideline for lymphoma patients infected with COVID-19. Percival et al[19] compiled a list of treatment recommendations for patients with hematologic malignancies during the COVID-19 pandemic. Further, more trials on COVID-19 vaccines on these patients should be done along with current therapies of hematologic disease to reveal the appropriate therapies in which these vaccines are effective.

FOOTNOTES

Author contributions: Sahu T, Verma HK, Lvks B wrote and revised the letter.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: Germany
Sahu T et al. SARS-CoV-2 infection in lymphoid malignancies

ORCID number: Tarun Sahu 0000-0002-2721-7432; Henu Kumar Verma 0000-0003-1130-8783; Bhaskar Lvks 0000-0003-2977-6454.

S-Editor: Wang JJ
L-Editor: Filipodia
P-Editor: Wang JJ

REFERENCES


